FDA panel: cough meds should stay over-the-counter
A panel of medical experts said Tuesday that cough medicines like Robitussin and Nyquil should continue to be sold over-the-counter, despite increased abuse among teenagers that has prompted calls to restrict sales of the products.
The Food and Drug Administration panel voted 15-9 against a proposal that would require a doctor's note to buy medicines containing dextromethorphan, an ingredient found in more than 100 over-the-counter medications.
The FDA is not bound to follow the group's advice, though it often does. Specifically, panelists were asked if the ingredient should be "scheduled," a regulatory move designed to decrease access to drugs with high potential for abuse.
"For me there was no data to show us that scheduling this product would decrease abuse," said panelist Janet Engle, professor and department head of pharmacy practice at the University of Illinois.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- FDA hopes hospitals will switch to newly regulated pharmacies
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Why You Should Involve Patients in Nursing Handoffs
- Douglas Hawthorne—A Chance to Do Something Big
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- Substance Abuse Resurfaces Among Anesthesiologists in Training
- The 5 Biggest Healthcare Finance Trouble Spots
- 'Country Doctor of the Year' Embraces Challenges of Rural Medicine